Furthermore, it inhibited tau aggregation and cytotoxicity in vitro, and it reduced the levels of phosphorylated tau, neuroinflammation, and synapse loss in the brain of a PS19 mouse model of AD, thus rescuing the cognitive deficits [149]. The gene discussed is MAPT; the disease is Alzheimer disease.